UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Deciphera	Pharmaceu	iticals,	Inc.
------------------	-----------	----------	------

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

24344T101

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☑ Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 24344T101	SCHEDULE 13G/A	Page 2 of 8 Pages
---------------------	----------------	-------------------

4	NAME OF REPORTING PERSONS			
1	OrbiMed Capital LLC			
			TE BOX IF A MEMBER OF A GROUP	
2	(a) o	11011111		
((b) o	(b) o		
	SEC USE ONLY	SEC USE ONLY		
3				
	CITIZENSHIP OR PLACE OF ORGANIZATION			
4				
	Delaware	Ι	SOLE VOTING POWER	
		5	SOLE VOTING FOWER	
NITIN	NUMBER OF		0	
	HARES	6	SHARED VOTING POWER	
	EFICIALLY NED BY		1,256,371	
E	EACH		SOLE DISPOSITIVE POWER	
	PORTING ERSON	7		
	WITH		0	
			SHARED DISPOSITIVE POWER	
		8	1,256,371	
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
9	1,256,371			
(CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o			
10				
	DED CENTE OF CLASS DEDDESENTED BY AMOUNT IN DOW (6)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	2.46%			
	TYPE OF REPOR	TING PER	RSON	
12		00		

CUSIP No. 24344T101	SCHEDULE 13G/A	Page 3 of 8 Pages
---------------------	----------------	-------------------

NAME OF REPORTING PERSONS OrbiMed Advisors LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) 0 (b) 0 SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION Delaware SOLE VOTING POWER NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SHARED DISPOSITIVE POWER 8 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0,51% TYPE OF REPORTING PERSON 12 TYPE OF REPORTING PERSON					
OrbiMed Advisors LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 0 SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12 TYPE OF REPORTING PERSON	1	NAME OF REPORTING PERSONS			
2 (a) 0 (b) 0 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 5 NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 7 SOLE DISPOSITIVE POWER 8 SHARED DISPOSITIVE POWER 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12 TYPE OF REPORTING PERSON		OrbiMed Advisors	OrbiMed Advisors LLC		
(b) o SEC USE ONLY 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 O SHARED SHARED SEACH REPORTING PERSON WITH SHARED DISPOSITIVE POWER 8 257,800 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 O 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51%		CHECK THE API	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 5 NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE DISPOSITIVE POWER 257,800 8 SHARED DISPOSITIVE POWER 257,800 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0,51% 12 TYPE OF REPORTING PERSON	2				
3 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware SOLE VOTING POWER 5 0 SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SHARED DISPOSITIVE POWER 257,800 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12 TYPE OF REPORTING PERSON		1			
A Delaware Sole voting power Survey Sole voting power	3	SEC OSE ONET	SEC USE ONLI		
A Delaware Sole voting power Survey Sole voting power					
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON	4	CITIZENSHIP OF	CITIZENSHIP OR PLACE OF ORGANIZATION		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 TYPE OF REPORTING PERSON		Delaware			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o TO PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 TYPE OF REPORTING PERSON			_	SOLE VOTING POWER	
SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 TYPE OF REPORTING PERSON TYPE OF REPORTING PERSON	NIT.			0	
OWNED BY EACH REPORTING PERSON WITH SHARED DISPOSITIVE POWER 8 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES O 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON	9	SHARES		SHARED VOTING POWER	
EACH REPORTING PERSON WITH SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON		OWNED BY EACH		257,800	
PERSON WITH SHARED DISPOSITIVE POWER 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 TYPE OF REPORTING PERSON TYPE OF REPORTING PERSON				SOLE DISPOSITIVE POWER	
SHARED DISPOSITIVE POWER 257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON			7		
257,800 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON					
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON			8	257 900	
9 257,800 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON					
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON	9		VIOUIVI D	SENERGINEER OWNED DE ENGLINEE ONTHOU LEGON	
10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON		· ·			
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.51% TYPE OF REPORTING PERSON	10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0			
11 0.51% TYPE OF REPORTING PERSON 12					
0.51% TYPE OF REPORTING PERSON 12	11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
12	11	0.51%			
	10	TYPE OF REPORTING PERSON			
		IA			

Item 1. (a) Name of Issuer:

Deciphera Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

200 Smith Street

Waltham, MA 02451

Item 2. (a) Name of Person Filing:

OrbiMed Capital LLC

OrbiMed Advisors LLC

(b) Address of Principal Business Office:

601 Lexington Avenue, 54th Floor

New York, NY 10022

(c) Citizenship:

Please refer to Item 4 on each cover page for each Reporting Person.

(d) Title of Class of Securities:

Common Stock, par value \$0.01 per share

(e) CUSIP No.:

24344T101

Item 3.

OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital LLC ("Capital") are investment advisors accordance with ss.240.13d-1(b)(1)(ii)(E).

Item 4. Ownership:

Information with respect to the Reporting Person's ownership as of December 31, 2019 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Reporting persons are holding 2.97% of the shares in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. No one such other person's interest in the securities whose ownership is reported here relates to more than five percent of the class. Advisors and Capital exercise investment and voting power over the shares through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Common Stock reported herein. Advisors disclaims beneficial ownership of the shares held indirectly by Capital, and Capital disclaims beneficial ownership of the shares held indirectly by Advisors.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2020

OrbiMed Advisors LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

By: /s/ Sven H. Borho

Name: Sven H. Borho Title: Member

By: /s/ Carl L. Gordon

Name: Carl L. Gordon Title: Member

OrbiMed Capital LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

By: /s/ Sven H. Borho

Name: Sven H. Borho Title: Member

By: /s/ Carl L. Gordon

Name: Carl L. Gordon Title: Member

EXHIBIT A JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this Schedule 13G/A dated February 14, 2020 (the "Schedule 13G/A"), with respect to the Common Stock, par value \$0.01 per share, of Deciphera Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 14, 2020.

OrbiMed Advisors LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

By: /s/ Sven H. Borho

Name: Sven H. Borho Title: Member

By: /s/ Carl L. Gordon

Name: Carl L. Gordon Title: Member

OrbiMed Capital LLC

By: /s/ Jonathan T. Silverstein

Name: Jonathan T. Silverstein

Title: Member

By: /s/ Sven H. Borho

Name: Sven H. Borho Title: Member

By: /s/ Carl L. Gordon

Name: Carl L. Gordon Title: Member